Cannabis Testing Global Market Report 2024

The cannabis testing market size has grown rapidly in recent years. It will grow from $2.54 billion in 2023 to $3 billion in 2024 at a compound annual growth rate (CAGR) of 18.4%. Historical growth can be attributed to the globalization of the cannabis market, increasing concerns about consumer safety, adherence to regulatory compliance, assurance of product quality, prioritizing public health and safety, and the drive for supply chain transparency.

The cannabis testing market size is expected to see rapid growth in the next few years. It will grow to $6.05 billion in 2028 at a compound annual growth rate (CAGR) of 19.1%. Anticipated growth in the upcoming period is tied to the ongoing legalization efforts, the implementation of stricter regulations, a focus on quality control within cultivation processes, the use of genetic testing, a surge in research and development, and the elevation of public awareness and education. Major trends expected in this forecast period encompass technological advancements, refining quality control within cultivation practices, the integration of microbial testing, profiling cannabinoids, and rigorous testing for pesticides and residues.

The expanding utilization of cannabis for medicinal purposes is anticipated to drive the growth trajectory of the cannabis testing market. Cannabis has gained prominence as a therapeutic agent, notably for alleviating tension, muscle issues, and reducing nausea and vomiting post-chemotherapy. Its efficacy in calming epileptic seizures and mitigating seizure intensity further underscores its medicinal value. According to the World Health Organization's 2022 statistics, approximately 2.5% of the global population, among the 147 million surveyed individuals, reported cannabis consumption. This surge in cannabis usage for medicinal applications acts as a significant impetus propelling the demand for cannabis testing services and solutions. As the therapeutic use of cannabis continues to expand, the cannabis testing market is poised to witness substantial growth to ensure product quality, safety, and regulatory compliance in the evolving landscape of medicinal cannabis.

The anticipated rise in neurological conditions is set to propel the growth trajectory of the cannabis testing market. Neurological conditions encompass a spectrum of disorders affecting the nervous system, comprising the brain, spinal cord, and peripheral nerves, leading to diverse cognitive, motor, and sensory impairments. Within the realm of neurological conditions, cannabis testing assumes significance as a tool for analyzing cannabinoids. This analysis aims to explore the potential therapeutic benefits of cannabis and its effects on symptoms associated with these conditions, such as pain, spasticity, and seizures. According to the World Federation of Neurology's findings in October 2023, over 40% of the global population currently experiences some form of neurological condition. Alarmingly, this burden is projected to nearly double by 2050. This surge in neurological conditions fuels the demand for cannabis testing, as researchers and medical professionals increasingly explore cannabis-based therapies to address symptoms and enhance the quality of life for individuals affected by these conditions. As the prevalence of neurological disorders continues to grow, the cannabis testing market is poised to expand, driven by the quest for effective treatments and therapeutic interventions within this domain.

Strategic partnerships have become a prominent trend among major industry players, aimed at bolstering their market positions. A notable instance is the collaboration forged in March 2022 between Digipath Inc., a US-based cannabis testing laboratory, and CASPR Technologies, a Nigeria-based provider specializing in smart environmental indoor technology for healthcare settings. This partnership between Digipath and CASPR entails an initiative to validate and assess the effectiveness of CASPR's technology in botanical applications, with a specific focus on cannabis and hemp. Through this collaboration, Digipath aims to leverage its testing expertise to evaluate the functionality and suitability of CASPR's technology within the realm of cannabis and hemp, highlighting the industry's increasing emphasis on strategic alliances to advance technological innovations and solutions within the cannabis testing landscape.

Major companies within the cannabis testing market are heavily invested in pioneering innovative tests, notably the development of roadside cannabis tests, to cater to the critical need for accurate impairment assessment. This strategic focus aims not only to fulfill this essential requirement but also to establish a competitive advantage in the market. Roadside cannabis tests function as diagnostic tools employing neurodiagnostics to evaluate recent cannabis use and associated impairment. An illustrative example is the April 2023 launch of OcuPro by Oculogica, a US-based medical device manufacturer. OcuPro stands as a groundbreaking roadside cannabis test utilizing neurodiagnostics to precisely assess recent cannabis use and the resultant impairment. Piloted in various Missouri police departments, this device operates by recording and analyzing eye-pupil characteristics, effectively distinguishing recent cannabis use within a narrow timeframe of 60-90 minutes from usage occurring over several hours. In contrast to traditional tests reliant on THC analysis from bodily samples, OcuPro directly addresses the pressing need for a scientifically validated impairment test specifically for recent cannabis use. This innovation holds immense significance in enforcing regulations against driving under the influence of cannabis, underscoring the pivotal role of advanced testing methodologies in ensuring road safety and regulatory compliance.

In May 2023, ACT Laboratories, a prominent US-based network specializing in cannabis and hemp testing, completed the acquisition of Green Scientific Labs for an undisclosed sum. This strategic acquisition was directed towards broadening and diversifying its portfolio, specifically in the realm of ready-to-drink (RTD) products. Green Scientific Labs, known for its expertise in testing hemp, cannabis, and marijuana, operates as a testing laboratory within the United States. ACT Laboratories' acquisition of Green Scientific Labs represents a strategic move to leverage Green Scientific Labs' proficiency in testing these substances, aiming to expand and enhance its offerings within the ready-to-drink (RTD) product category. This strategic alignment through acquisition signifies ACT Laboratories' commitment to fortifying its presence and capabilities within the cannabis and hemp testing landscape while leveraging the specialized expertise of Green Scientific Labs to fuel growth and diversification within the RTD market segment.

Major companies operating in the cannabis testing market report are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, SGS Canada Inc., Eurofins Scientific SE, Agilent Technologies Inc., Sartorius AG, PerkinElmer Inc., Shimadzu Corporation, Waters Corporation, Ab Sciex LLC, LGC Limited, Tentamus Group, Phenomenex Inc., Saskatchewan Research Council (SRC), Restek Corporation, SC Laboratories, Anresco Labs, Praxis Labs, Accelerated Technology Laboratories Inc., GreenLeaf Lab, ACT Laboratories, PharmLabs LLC, Abko Labs, BelCosta Labs, Medicinal Genomics, CW Analytical Laboratories Inc, DigiPath Inc, CDX Analytics, Steep Hill Halent Laboratories Inc.

North America was the largest region in the cannabis testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabis testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cannabis testing encompasses various test types including potency, pesticide screening, residual solvent screening, heavy metal analysis, terpene profiling, mycotoxin detection, and more. Instruments utilized for this purpose involve technologies such as chromatography, spectroscopy, and others, featuring different portability options such as stand-alone and handheld devices. These tools are deployed in testing laboratories, drug manufacturers, research institutes, and various other end-user settings.

The cannabis testing market research report is one of a series of new reports that provides cannabis testing market statistics, including global market size, regional shares, competitors with a cannabis testing market share, detailed cannabis testing market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis testing industry. This cannabis testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cannabis testing market includes revenues earned by entities by cannabinoid profile & potency analysis, heavy metal screening, mycotoxin screening, molds & mildews, pesticides & herbicides and residual solvents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.